Logo

Transforming good science
into great medicine
for rare genetic diseases.

Deep and diversified product pipeline

Developing multiple clinical-stage programs in parallel                                  

Focused on serious rare and ultra-rare diseases

Working with patients and medical professionals to treat rare diseases

Dedicated to creating new treatments 

Join a high-performance team focused on rare diseases


 

August 2, 2018
Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update

July 27, 2018
Ultragenyx to Host Conference Call for Second Quarter 2018 Financial Results and Corporate Update

July 26, 2018
Ultragenyx Announces First Patient Dosed in Phase 1/2 study of DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa); FDA Grants Fast Track Designation to Gene Therapy Program

  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Camille Bedrosian, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Message from BIO
  • Medicines
    • Crysvita®
    • Mepsevii™
  • Pipeline
    • Burosumab for TIO
    • UX007 for FAOD
    • UX007 for Glut1 DS
    • DTX 301 for OTC
    • DTX 401 for GSDIa
    • Presentations & Publications
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • Glut1 DS
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • SEC Filings
    • Stock Information
      • Analyst Coverage
    • Investor FAQ
    • Contact Us
  • Careers
    • Commitment
    • Benefits
    • Interns
    • Jobs
  • Partnering
    • Current Partnerships
  • Contact
    • Driving Directions
  • Home
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Camille Bedrosian, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Message from BIO
  • Medicines
    • Crysvita®
    • Mepsevii™
  • Pipeline
    • Burosumab for TIO
    • UX007 for FAOD
    • UX007 for Glut1 DS
    • DTX 301 for OTC
    • DTX 401 for GSDIa
    • Presentations & Publications
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • Glut1 DS
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • SEC Filings
    • Stock Information
      • Analyst Coverage
    • Investor FAQ
    • Contact Us
  • Careers
    • Commitment
    • Benefits
    • Interns
    • Jobs
  • Partnering
    • Current Partnerships
  • Contact
    • Driving Directions
  • Privacy Policy
© 2018 Ultragenyx PharmaceuticalWebsite Design: Hane Chow, Inc.
  • Privacy Policy